Subcutaneous and perineural botulinum toxin type A for neuropathic pain: A descriptive review

Clinical Journal of Pain

Volumn 29, Issue 11, 2013, Pages 1006-1012

  Fabregat, Gustavo ^a   De Andrés, José ^b   Villanueva Pérez, Vicente L ^a   Asensio Samper, Juan M ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

botulinum toxin; neuralgia; neuropathic pain; subcutaneous

Indexed keywords

ANTIBIOTIC AGENT; BOTULINUM TOXIN A;

ANTIBIOTIC THERAPY; BRACHIAL PLEXUS NEUROPATHY; CARPAL TUNNEL SYNDROME; CHRONIC PAIN; COMPLEX REGIONAL PAIN SYNDROME; DATA BASE; DESCRIPTIVE RESEARCH; DIABETIC NEUROPATHY; DRUG MECHANISM; DRUG SAFETY; FACE PAIN; HUMAN; INJECTION SITE INFECTION; MEDLINE; NAUSEA; NEURALGIA; NEURITIS; NEUROPATHIC PAIN; PARESIS; PATHOPHYSIOLOGY; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PUBLICATION; REVIEW; SCIATIC NEUROPATHY; SCIATICA; SYMPATHETIC BLOCKING; SYSTEMATIC REVIEW; TRIGEMINUS NEURALGIA; VOMITING;

BOTULINUM TOXINS, TYPE A; DATABASES, FACTUAL; HUMANS; INJECTIONS, SUBCUTANEOUS; NEURALGIA;

EID: 84885433412     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0b013e31827eafff     Document Type: Review

References (42)

1. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630-1635.
2. Bouhassira D, Lanteri-Minet M, Attal N, et al. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008;136:380-387.
3. Oster G, Harding G, Dukes E, et al. Pain, medication use and health-related quality of life in older persons with post-herpetic neuralgia: results from a population-based survey. J Pain. 2005;6:356-363.
4. Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology. 2007;68:1178-1182.
5. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacological management of neuropathic pain: evidence-based recommendations. Pain. 2007;132:237-251.
6. Ruiz Huete C, Bermejo PE. Botulinum toxin type A in the treatment of neuropathic pain in a case of postherpetic neuralgia. Neurologia. 2008;23:259-262.
7. Uyesugi B, Lippincott B, Dave S. Treatment of a painful keloid with botulinum toxin type A. Am J Phys Med Rehabil. 2010;89:153-155.
8. Argoff CE. A focused review on the use of botulinum toxins for neuropathic pain. Clin J Pain. 2002;18(suppl):S177-S181.
9. Breuer B, Sperber K, Wallenstein S, et al. Clinically significant placebo analgesic response in a pilot trial of botulinum B in patients with hand pain and carpal tunnel syndrome. Pain Med. 2006;7:16-24.
10. Liu HT, Tsai SK, Kao MC, et al. Botulinum toxin A relieved neuropathic pain in a case of post-herpetic neuralgia. Pain Med. 2006;7:89-91.
11. Sotiriu E, Apalla Z, Panagiotidou D, et al. Severe post-herpetic neuralgia successfully treated with botulinum toxin A: three case reports. Acta Derm Venereol. 2009;889:214-215.
12. Xiao L, Mackey S, Hui H, et al. Subcutaneous injection of botulinum toxin A is beneficial in postherpetic neuralgia. Pain Med. 2010;11:1827-1833.
13. Jabbari B, Maher N, Difazio MP. Botulinum toxin A improved burning pain and allodynia in two patients with spinal cord pathology. Pain Med. 2003;4:206-210.
14. Yuan RY, Sheu JJ, Yu JM, et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology. 2009;72:1473-1478.
15. Apfel SC. Botulinum toxin for neuropathic pain? Neurology. 2009;72:1456-1457.
16. Carroll I, Clark JD, Mackey S. Sympathetic block with botulinum toxin to treat complex regional pain syndrome. Ann Neurol. 2009;65:348-351.
17. Borodic GE, Acquadro MA. The use of botulinum toxin for the treatment of chronic facial pain. J Pain. 2002;3:21-27.
18. Piovesan EJ, Teive HG, Kowacs PA, et al. An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology. 2005;65:1306-1308.
19. Zuniga C, Diaz S, Piedimonte F, et al. Beneficial effects of botulinum toxin type A in trigeminal neuralgia. Arq Neuro-psiquiatr. 2008;66(3-A):500-503.
20. Volcy M, Teppr SJ, Rapoport AM, et al. Botulinum toxin A for the treatment of greater occipital neuralgia and trigeminal neuralgia: a case report with pathophysiological considerations. Cephalalgia. 2005;26:336-340.
21. Ngeow WC, Nair R. Injections of botulinum toxin type A into trigger zone of trigeminal neuralgia as a means to control pain. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109: e47-e50.
22. Yoon SH, Merril RL, Choi JH, et al. Use of botulinum toxin type A injection for neuropathic pain after trigeminal nerve injury. Pain Med. 2010;11:630-632.
23. Allam N, Brasil-Neto JP, Brown G, et al. Injections of botulinum toxin type A produce alleviation of intractable trigeminal neuralgia. Clin J Pain. 2005;21:182-184.
24. Turk U, Ilhan S, Alp R, et al. Botulinum toxin and intractable trigeminal neuralgia. Clin Neuropharmacol. 2005;28: 161-162.
25. Bohluli B, Botamedi MH, Bagheri SC, et al. Use of botulinum toxin A for drug-refractory trigeminal neuralgia: preliminary report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;111:47-50.
26. Kapural L, Stillman M, Kapural M, et al. Botulinum toxin occipital nerve block for the treatment of severe occipital neuralgia: a case series. Pain Pract. 2007;7:337-340.
27. Taylor M, Silva S, Cottrell C. Botulinum toxin type A in the treatment of occipital neuralgia: a pilot study. Headache. 2008;48:1476-1481.
28. Ranoux D, Attal N, Morain F, et al. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol. 2008;64:274-283.
29. Tsai CP, Liu CY, Lin KP, et al. Efficacy of botulinum toxin type a in the relief of carpal tunnel syndrome: a preliminary experience. Clin Drug Investig. 2006;26:511-515.
30. Fabregat G, Asensio-Samper JM, Palmisani S, et al. Subcutaneous botulinum toxin for chronic post-thoracotomy pain. Pain Pract. 2012. [Epub ahead of print]. doi: 10.1111/j.1533-2500.2012.00569.x.
31. Luvisetto S, Marinelli S, Cobianchi S, et al. Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain. Neuroscience. 2007;145:1-4.
32. Marinelli S, Luvisetto S, Cobianchi S, et al. Botulinum neurotoxin type A counteracts neuropathic pain and facilitates functional recovery after peripheral nerve injury in animal models. Neuroscience. 2010;171:316-328.
33. Bach-Rojecky L, Relja M, Lackovic Z. Botulinum toxin type A in experimental neuropathic pain. J Neural Transm. 2005;112:215-219.
34. Bach-Rojecky L, Salkovic-Petrisic M, Lackovic Z. Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection. Eur J Pharmacol. 2010;633:10-14.
35. Dressler D, Bigalke H. Pharmacology of botulinum toxin drugs. In: Truong D, Dressler D, Hallet M, eds. Manual of Botulinum Toxin Therapy. New York: Cambridge University Press; 2009:13-22.
36. Yaraskavitch M, Leonard T, Herzog W. Botox produces functional weakness in non-injected muscles adjacent to the target muscle. J Biomech. 2008;41:897-902.
37. Cui M, Khanijou S, Rubino J, et al. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107:125-133.
38. Smith CP, Vemulakonda VM, Kiss S, et al. Enhanced ATP release from rat bladder urothelium during chronic bladder inflammation: effect of botulinum toxin A. Neurochem Int. 2005;47:291-297.
39. Gazerani P, Pedersen NS, Staahl C, et al. Subcutaneous botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain. 2009; 141:60-69.
40. Tugnoli V, Capone JG, Eleopra R, et al. Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilation in human skin. Pain. 2007;130:76-83.
41. Antonucci F, Rossi C, Gianfranceschi L, et al. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci. 2008;28:3689-3696.
42. Byrnes ML, Thickbroom GW, Wilson SA, et al. The cortico-motor representation of upper limb muscles in writer's cramp and changes following botulinum toxin injection. Brain. 1998; 121(pt 5):977-988.